Bacterially Derived Minicells Carrying Cancer Drugs Pairing a Targeted Payload With an Interferon Trigger

This application covers compositions and methods for treating cancer using tiny particles derived from bacteria, called minicells, loaded with an anti-cancer drug and combined with an agent that switches on the body’s interferon response. The applicant is the Sydney-based biotechnology company EnGeneIC Molecular Delivery Pty Ltd.

The Problem

Most cancer drugs are still given systemically, meaning they travel through the whole body rather than only to the tumour. The specification sets out why that is a problem. Healthy tissues and organs are exposed to a cytotoxic drug they gain nothing from, which produces the toxicity familiar from conventional chemotherapy. The effect compounds itself, because poor bioavailability and a large volume of distribution mean the dose has to be pushed high just to get a useful amount to the tumour.

There are practical costs too. Systemic administration is invasive, often requiring a catheter placed in a major blood vessel, and it carries local complications such as phlebitis and tissue damage where a drug leaks out of the vein, a well-known issue with drug classes such as the vinca alkaloids and anthracyclines.

Sitting behind all of that is resistance. Some tumours do not respond from the outset, and others stop responding after initially shrinking, so a delivery system alone does not solve the clinical problem if the tumour has already learned to survive the drug being delivered.

What This Invention Does

The approach uses intact minicells derived from bacteria as a delivery vehicle. Minicells are small, non-living particles produced when a bacterium divides abnormally at its pole, and they can be loaded with a drug payload and coated with a targeting antibody so that they attach to and are taken up by tumour cells rather than healthy ones. That concentrates a potent cytotoxic agent where it is needed and keeps systemic exposure low.

The invention claimed here is the combination. The composition pairs the anti-neoplastic agent with an interferon type I agonist, an interferon type II agonist, or both together. Interferons are signalling proteins the immune system uses to raise the alarm about infected or abnormal cells. Adding an interferon agonist alongside the delivered drug is intended to recruit an immune response against the tumour rather than relying on the chemical payload alone, which is the same logic that drives modern immunotherapy combinations.

Key Features

• Bacterially derived minicells. Non-living particles derived from bacteria serve as the drug carrier.
• Anti-neoplastic payload. The minicells carry a cytotoxic anti-cancer agent to the tumour.
• Interferon type I agonist. The composition may include an agent that activates the type I interferon pathway.
• Interferon type II agonist. A type II interferon agonist may be used instead, engaging a different arm of the immune response.
• Combined agonists. Type I and type II agonists may be used together in the same composition.
• Reduced systemic exposure. Targeted delivery is intended to lower the whole-body toxicity associated with conventional chemotherapy dosing.

Who Is Behind It

The applicant is EnGeneIC Molecular Delivery Pty Ltd, part of the EnGeneIC group, a clinical-stage biotechnology company founded in Sydney that has built its work around a minicell delivery platform it calls the EnGeneIC Dream Vector. The named inventors are Himanshu Brahmbhatt and Jennifer MacDiarmid, the company’s co-founders and the researchers behind the original minicell work. The application is a divisional of Australian application 2019311380 and claims priority from United States provisional applications filed in July 2018 and January 2019.

Why It Matters

Targeted delivery has been one of the central goals of cancer therapeutics for decades, and the field has produced several distinct answers to it, including antibody-drug conjugates, liposome formulations and nanoparticle carriers. A bacterially derived minicell is an unusual entry in that list because it is a biological container rather than a synthetic one, large enough to hold a meaningful drug load and naturally recognised by parts of the immune system.

That last point is what makes the combination claimed here interesting. Rather than treating the immune response to a bacterial particle as a nuisance to be engineered away, the composition adds an interferon agonist to lean into it, aiming for a therapy that both delivers a cytotoxic drug and provokes an immune attack on the tumour. Whether that translates into clinical benefit is a question for trials, but the underlying idea, combining local delivery with immune activation, reflects where a good deal of oncology development has moved.

Related Concepts

• Minicell – the bacterially derived particle used as a drug carrier.
• Cancer immunotherapy – the broader field of recruiting the immune system against tumours.
• Interferon – the signalling proteins the agonists in this composition activate.
• Antibody-drug conjugate – a different route to the same targeted delivery goal.
• Drug delivery – the engineering discipline this invention sits within.
• Multiple drug resistance – the tumour resistance problem the specification identifies.

---

AU 2026202046 was published in the Australian Official Journal of Patents on 9 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.